WEST LAFAYETTE, IN — Bioanalytical Systems, Inc. (NASDAQ:BASI)

today announced the appointment of Jeffrey Potrzebowski as Chief Financial Officer and James S.

Bourdage, Ph.D., as Vice President Bioanalytical Operations.

BASi President & CEO Jacqueline Lemke said, “These appointments represent significant steps

forward in our continuing program to build a management team with the depth, experience and

dedication to take BASi to the next level and achieve our goals for growth and profitability. Each

of these senior executives brings an impressive record of accomplishment to his new role at BASi:

Jeff Potrzebowski in financial management, reporting, planning and related public company CFO

functions; and Jim Bourdage in the leadership and management of large global laboratory

operations in the pharmaceutical and biotech industries. We welcome Jeff and Jim to BASi, and

look forward to their contributions to our continued success.”

Jeffrey Potrzebowski, CPA

Jeffrey Potrzebowski joins BASi after serving since 2006 in various positions of increasing

responsibility with Oerlikon Drive Systems, Lafayette, Indiana, most recently as Chief Financial

Officer of this $800 million manufacturer of gear and drive solutions, where he was responsible for

the management and control of financial performance of the Operating Segment reporting to the

Segment CEO. Earlier, he was Senior Vice President and Chief Financial Officer of Remy

International, Anderson, Indiana, a producer of electrical automotive parts with sales in excess of

$1.2 billion. Previously, Mr. Potrzebowski was Senior Vice President and Chief Financial Officer

of Great Lakes Chemical, Indianapolis, a $1.6 billion specialty chemical company, which he joined

in 1993.R

Mr. Potrzebowski began his career with Price Waterhouse in Toledo. He received a BA in

Accounting from Toledo University in 1975 and a CPA in 1976.

James S. Bourdage, Ph.D.

James S. Bourdage was Executive Director Biopharmaceutical CMC Solutions at Covance Inc.,

Greenfield, Indiana, since 2011, where he was responsible for the US Biotechnology CMC

operation of this $2.4 billion drug development services organization. Earlier, he was Senior

Director, Bioanalytical Sciences, at Pharmathene, Inc., Annapolis, Maryland, a biodefense

company with more than $300 million in government contracts. From 2003 to 2009, Dr. Bourdage

was Global Research Advisor and Team Leader, Laboratory for Experimental Medicine at Eli Lilly

Co., Indianapolis, where his responsibilities included oversight of biotherapeutic immunogenicity

and biomarker assay development to support global clinical trials. Previously, he was Senior

Research Scientist, Drug Absorption and Transport at Pharmacia (Upjohn), Kalamazoo, Michigan,

where he received the Upjohn Corporate Special Recognition Award in 1992 and the Quality

Control Achievement Award in 1993.

Dr. Bourdage received a Ph.D. in Immunochemistry from the University of Illinois in 1979. He

is a member of the American Society of Clinical Pathologists and the American Association of

Pharmaceutical Scientists, and is the author of numerous scientific papers.

About Bioanalytical Systems, Inc.

BASi is a pharmaceutical development company providing contract research services and monitoring

instruments to the world’s leading drug development companies and medical research organizations.

The company focuses on developing innovative services and products that increase efficiency and

reduce the cost of taking a new drug to market. Visit www.BASinc.com for more about BASi.

This release contains forward-looking statements that are subject to risks and uncertainties including, but not limited to,risks and uncertainties related to changes in the market and demand for our products and services, the development,marketing and sales of products and services, changes in technology, industry standards and regulatory standards, and various market and operating risks detailed in the company’s filings with the Securities and Exchange Commission.